Tag Archive for: Alzheimer’s

Novo Holdings participates in $372.5 million Series D financing of MapLight Therapeutics to advance differentiated CNS therapies

/in

Financing to support Phase 2 trials of lead program for schizophrenia and Alzheimer’s disease psychosis, and expansion of CNS pipeline San Francisco, US, 28 July 2025 – Novo Holdings, a leading life science investor, today announced its participation in a $372.5 million Series D financing of MapLight Therapeutics (“MapLight”), a clinical-stage biopharmaceutical company focused on improving […]

Read more

This week’s hot topic: Why Pharma will have to play the long game on Alzheimer’s drugs

/in

By Stephen Adams, Optimum Strategic Communications Few people expected England and Wales’s drugs spending watchdog, the National Institute for Health and Care Excellence (“NICE”), to approve Eli Lilly’s new dementia drug donanemab for use on the NHS last week.  At a reputed annual cost of at least £60,000 a year, including the care bill, it […]

Read more

AstronauTx appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team

/in

Jane Rhodes appointed as Chief Executive Officer Magnus Ivarsson appointed as Chief Translation and Early Development Officer London UK, 1 October 2024 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders, today announces the appointment of Dr Jane Rhodes, PhD, MBA, as Chief Executive Officer (CEO) and member […]

Read more

Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases

/in

Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA […]

Read more

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

/in

Significant appointments of industry and academic experts to support Phase II development of ASN51 in Alzheimer’s disease Lausanne, SWITZERLAND and San Francisco, CA, USA, 6 March 2024 – Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board […]

Read more